Eighteen-month follow-up of glipizide and human insulin combination in the treatment of type II diabetes mellitus

Abstract EN

This study reports a follow up of 29 Type II Diabetic patients with secondary drug failure treated by a combination of Human Insulin and Glipizide.

During their follow-up, Insulin therapy was instituted following discontinuation of the maximum permissible dose of sulphonylureas for variable periods of time and thereafter Glipizide was added to Insulin treat-ment.

Their diabetic control was assessed by checking the fasting and 2hr postprandial venous blood glucose values, HbAlc and weight changes.

These results were then compared in various phases of treatment, i.e.

Phase I: Gral hypoglycemic agents, Phase II: Insulin alone (mean duration 2.55 ± 1.75 years), and Phase III: Human Insulin and Glipizide combina-tion (mean duration 1.93 ± 0.72 years).

It was found that patients in Phase III showed an overall improved gycemic control compared to Phase land II.

HbA^dropped to 9.11 ± 3.25 in Phase III compared to 11.13 ± 2.75 in Phase II and 11.45 ± 2.07 in Phase I.

There was a weight gain of 3.66 ± 6.69 kg in Phase II as compared to a net loss of 1.14 ± 5.93 kg in Phase III.

The mean daily retirement of Insulin in Phase II of 65.19 u decreased to 49.62 u in Phase III.

No relationship was established between the initial high Body Mass Index and initial C-peptides of responders and non-responders to combination therapy.

This study highlights the value of combination therapy of Glipizide plus Human Insulin in the control of diabetes after secondary failure in Type II diabetic patients.